Optimism on Diabetes Medication Grows -- MannKind and Amylin Benefit
November 02 2011 - 8:16AM
Marketwired
In the United States alone, more than 21 million people suffer from
diabetes, and the number is growing at a rate of 10 percent
annually. This rapid growth has provided significant opportunities
for pharmaceutical companies who are able to develop new therapies
to address type 1 and 2 diabetes. The Paragon Report examines
investing opportunities in the Biotechnology Industry and provides
equity research on MannKind Corporation (NASDAQ: MNKD) and Amylin
Pharmaceuticals, Inc. (NASDAQ: AMLN). Access to the full company
reports can be found at:
www.paragonreport.com/MNKD
www.paragonreport.com/AMLN
According to Frost & Sullivan research titled "US Diabetes
Drug Delivery - Patient Perspective," the future of diabetes
treatments is in the convenient drug delivery methods. Type-1
diabetic patients are most likely to prefer a twice-a-day oral
dosing regimen, while type-2 diabetic patients are also expected to
prefer a twice-a-day oral dosing regimen or a twice-a-day
patch.
MannKind's leading drug candidate, Alfrezza, is an ultra-rapid
acting inhalable insulin that (if approved) will allow diabetes
patients to inhale Afrezza before a meal. MannKind is trying to
show the FDA that the drug does not cause dangerous side effects to
a patient's heart.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the biotechnology industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Amylin Pharmaceuticals is engaged in the discovery, development
and commercialization of drug candidates for the treatment of
diabetes, obesity and other diseases. Last month shares of the
company rose the most in more than six months after its Byetta drug
developed with Eli Lilly & Co. won expanded approval for use
with the world's top-selling insulin to treat Type 2 diabetes.
The drug brought in $559 million for San Diego-based Amylin last
year, almost 85 percent of the company's revenue, according to data
Bloomberg compiled. The drug accounted for $151 million in sales
for Indianapolis-based Lilly last year.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Apr 2024 to May 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From May 2023 to May 2024